

Cite this: *Chem. Sci.*, 2021, 12, 10076

All publication charges for this article have been paid for by the Royal Society of Chemistry

Received 29th April 2021
Accepted 28th June 2021

DOI: 10.1039/d1sc02396a

rsc.li/chemical-science

Desymmetrization of pibrentasvir for efficient prodrug synthesis†

Eric A. Voight,^a Stephen N. Greszler,^a John Hartung,^b Jianguo Ji,^b Russell C. Klix,^b John T. Randolph,^a Bhadra H. Shelat,^b Jan E. Waters^a and David A. DeGoey^a

A novel and practical desymmetrization tactic is described to access a new class of pibrentasvir prodrugs. The homotopic benzimidazoles of pibrentasvir (PIB) are differentiated *via* a one-pot di-Boc/mono-de-Boc selective *N*-Boc protection and formaldehyde adduct formation sequence, both enabled by crystallization-induced selectivity. The first step represents the only known application of the Horeau principle of statistical amplification for C_2 -symmetric polyheterocycle regioselective functionalization. The resulting versatile intermediate is employed in the high-yielding preparation of several pibrentasvir prodrug candidates.

Introduction

Mavyret® is a pan-genotype treatment for hepatitis C virus (HCV) containing glecaprevir, an NS3/4A protease inhibitor, and pibrentasvir (1, PIB), an NS5A inhibitor (Fig. 1).¹ As the first pan-genotypic 8 week cure for people suffering from HCV, Mavyret® was approved by the U.S. Food and Drug Administration (FDA) in 2017 for the treatment of genotype 1-6 chronic HCV after a 98% 8 week cure rate was reported for treatment-naïve patients without cirrhosis or with compensated cirrhosis.² Enabling formulations were required for further improving bioavailability due to challenging physicochemical properties,³ so a prodrug approach was pursued, resulting in the discovery of phosphates 2, 3, and 4.⁴

Pibrentasvir (1, PIB) is a large (MW 1113 g mol⁻¹) C_2 -symmetric drug molecule which presents several uniquely challenging structural features when considering a solubility-enhancing prodrug approach (Fig. 1). The end-cap amino acid fragments, methoxycarbonyl (Moc)-protected *O*-Me-L-threonines, are prone to epimerization, β -elimination, and facile Moc cleavage with nucleophiles and bases. For these reasons, preliminary attempts to attach cleavable prodrug moieties to the end-caps proved futile.⁴ The four PIB benzimidazole nitrogen atoms initially appeared too similar in reactivity to be functionalized selectively, complicated by the two tertiary aniline nitrogens and the fact that PIB exists as a mixture of tautomers and rotamers in solution.⁵ Finally, and most significantly when considering synthetic efficiency challenges, the C_2 -symmetric nature of PIB renders each end homotopic. This

feature facilitated efficient two-directional chain synthesis in the preparation of PIB⁶ with stereochemical purity enhancement *via* the Horeau principle.⁷ However, without a readily apparent internal functionalization or steric proximity effect to avoid bis(functionalization),⁸ a statistical mixture of products was anticipated and observed in early syntheses of 2–4.⁴

Since the seminal reviews by Schreiber⁹ and Magnus⁸ describing two-directional synthesis and terminus differentiation, this strategy has been used successfully in a number of additional complex molecule syntheses (Fig. 2). For example, in Hoye's synthesis of the annonaceous acetogenin (+)-parviflorin, bis(epoxide) 5 was desymmetrized *via* reaction with a limited quantity of a lithium acetylide, giving alcohol 6 (29%) along with recovered 5 (53%).¹⁰ Two syntheses from the Burke group utilized this approach, including a related annonaceous acetogenin, uvaricin (not shown), using a dihydroxylation,¹¹ and the C(37)-C(54) halichondrin B subunit, using an olefination/hydroboration/oxidation sequence to convert bis(lactone) 7 to




Fig. 1 Pibrentasvir (1) structure, challenging features, and PIB prodrugs 2–4.

^aDrug Discovery Science & Technology, AbbVie, Inc., 1 North Waukegan Road, North Chicago, Illinois, 60064-1802, USA. E-mail: eric.a.voight@abbvie.com

^bProcess Research and Development, AbbVie, Inc., 1 North Waukegan Road, North Chicago, Illinois, 60064-1802, USA

† Electronic supplementary information (ESI) available. See DOI: 10.1039/d1sc02396a






Fig. 2 Examples of desymmetrization reactions of complex C_2 -symmetric molecules.




Fig. 3 Benzimidazole nitrogen desymmetrizing and regioselective functionalization strategy.

desymmetrized primary alcohol **8** in 40% yield.¹² In a remarkably brief route to (+)-roxaticin that showcases this approach, the Krische group desymmetrized diol **9** *via* mono-selenide **10** formation in 50% yield.¹³ Our initial synthesis of prodrug **3** used a similar strategy, producing intermediate **di-Bn-3** in only 19%

yield from pibrentasvir. In each example, a maximum yield of 50% was expected and observed due to the standard statistical mixtures of starting material/mono/di-functionalized products (1 : 2 : 1 ratio) obtained in homotopic termini differentiation, requiring starting material recovery and resubjection to improve material throughput. In contrast, this work describes a rare example of highly controlled mono-functionalization of a complex C_2 -symmetric molecule *via* Horeau amplified di-Boc protection/crystallization-induced selective mono-Boc deprotection (de-Boc) with *n*-BuNH₂, giving mono-*N*-Boc-PIB **11** in 94% yield from PIB, a 5-fold increase in desymmetrization yield *versus* the original route. An overall yield of ~50% from PIB was a requirement for consideration of a pibrentasvir prodrug as a development candidate due to the high value of PIB, so this desymmetrization tactic was critical.


Results and Discussion

In addition to homotopic terminus differentiation challenges, potential strategies to selectively functionalize PIB had to simultaneously address benzimidazole regioisomer selectivity (Fig. 3). Since two equivalent PIB nitrogens are *para*-fluoro (“down” red) and two are *meta*-fluoro (“up” – blue), some electronic bias was anticipated. However, early routes to PIB prodrugs demonstrated poor alkylation selectivities under a variety of conditions with challenging isomer separations further complicating the aforementioned statistical terminus differentiation issue (Fig. 2).⁴ Since no direct PIB alkylation appeared to provide any useful levels of selectivity or clear opportunities for efficient end differentiation, a Boc protection strategy was envisioned to simplify the problem to a single benzimidazole regioselective alkylation. All reaction conditions would need to be mild enough to not degrade PIB and efficient enough to enable the 50% overall yield target. While considering the potential for biocatalytic or Miller peptide-based catalyst approaches for desymmetrization,¹⁴ approaches using simple reagents which could benefit from inherent substrate bias and/or solubility properties were prioritized.


Not surprisingly, initial attempts to mono-Boc protect PIB gave a mixture of six compounds (Scheme 1), reflecting a 1 : 2 : 1 statistical ratio of starting material **1**, mono-Boc (**11** + **12**), and di-Boc (**13** + **14** + **15**) isomers with a 3 : 1 ratio of down-mono-Boc **11** (Boc *para* to fluoro) to up-mono-Boc **12** (Boc *meta* to fluoro). This ratio favoring **11** was presumably influenced by the more nucleophilic nature of the nitrogens *para* to the fluorine. Following tedious chromatography, a 48% yield of mono-Boc isomers **11** and **12** was obtained. Slurrying the mixture in 3 : 1 MTBE/EtOAc gave a crystalline solid of **11** containing <1% **12** (3 : 1 **12**/**11** in the filtrate), indicating a significant solubility difference between mono-Boc benzimidazole regioisomers. This solubility difference would prove to be important in optimizing the formation of down-mono-Boc PIB **11**.

Reasoning that selective de-Boc of a mixture of di-Boc benzimidazoles **13**, **14**, and **15** may facilitate selective protection, and that both **13** and **14** could undergo Boc deprotection to give mono-down-Boc isomer **11** if relative rates of Boc cleavage were favorable, a complete reaction to a mixture of di-Boc






Scheme 1 Initial attempt to mono-Boc protect PIB, 1.



Scheme 2 Selective di-Boc to a mixture of 13, 14, and 15.



compounds **13**, **14**, and **15** was carried out (Scheme 2). Following initial optimization of solvent and temperature to minimize **15**,¹⁵ a 69 : 28 : 3 ratio of **13**, **14**, and **15**, respectively, was obtained. Since (up,down)-di-Boc isomer **14** contains both an up-Boc and a down-Boc, this result represents an 83 (69 + 28/2):17 (28/2 + 3) total down/up-*N*-Boc ratio (5 : 1). When considering all species containing at least one down-Boc benzimidazole (**13** and **14**), this mixture constitutes a 97 (69 + 28) : 3 ratio (32 : 1), provided all undesired up-Boc can be selectively cleaved. While the first Boc protection benefits from the electronic bias imparted by the fluorine atom, the enhancement observed in the second Boc protection can be considered an example of the Horeau principle of statistical amplification.⁷


The Horeau principle is typically invoked in asymmetric synthesis to, for example, explain the upgrade in optical purity of a low-ee scalemic sample through coupling to a bifunctional linker to form a C_2 /meso mixture which can be more easily separated at the expense of yield. A review on this topic recently appeared.⁷ Fig. 4 shows Horeau's first application of this principle in upgrading the enantiomeric purity of a 60% ee secondary alcohol to 87% ee by forming a mixture of C_2 /meso carbonates, removing the meso isomer, and cleaving the carbonate.¹⁶ In this example, since 20% (*R*) isomer becomes meso and 80% (*S*) isomer becomes meso (statistically), 32% of

Fig. 4 Original application of the Horeau principle of statistical amplification.¹⁶


the carbonate mixture is readily removed, leaving a 64 : 4 (16 : 1) ratio of (*R*)/(*S*) after carbonate cleavage (87% ee). A second cycle further enhances the mixture to 96% ee at the further expense of yield. In the present case, rather than the minor/major (or equivalent major/minor) reaction product **14** being an undesirable meso isomer, the resulting up/down di-Boc **14** still contains a desired down-Boc (Scheme 2). Therefore, down/up-*N* regioselectivity is enhanced from 5 : 1 to 32 : 1 via the Horeau principle of statistical amplification, with 97% of the total mixture containing at least one down-*N*-Boc. This constitutes the first known application of this principle for the regioselective functionalization of a C_2 -symmetric poly-heterocycle.¹⁷ However, while both **13** and **14** contain at least one down-Boc benzimidazole, their simultaneous selective conversion to down-mono-Boc **11** without further de-Boc to PIB remained a significant hurdle to accomplishing PIB desymmetrization.

Since mono-Boc regioisomers **11** and **12** showed favorable solubility differences in MTBE (*vide supra*), and it was anticipated that a primary aliphatic amine may deprotect the

Scheme 3 De-Boc of di-Boc mixture to give **11** selectively. De-Boc conditions: *n*-BuNH₂ (1.5 equiv.), MTBE (8 mL g⁻¹), 23 °C.



Scheme 4 One-pot di-Boc/mono-de-Boc with ACN solvent switch. Conditions: Boc_2O (1.9 equiv.), DMAP (0.1 equiv.), THF (5 mL g^{-1}), -40°C , 3 h; $n\text{-BuNH}_2$ (0.8 equiv.), MTBE (10 mL g^{-1}), 23°C , 18 h; $n\text{-BuNH}_2$ (1 equiv.), ACN (10 mL g^{-1}), 23°C , 21 h; mother liquor resubjection.



Scheme 5 One-pot hydroxymethylation/acylation of **11**.

benzimidazoles at a slow enough rate that mono-Boc **11** could be protected from further de-Boc to PIB by crystallization,¹⁸ the reaction solvent was switched from THF to MTBE and *n*-butylamine was added to the reaction mixture (Scheme 3). Much to our delight, under these conditions, up-Boc cleaved significantly faster than down-Boc, with **14** converting to **11** and **15** converting to **12** quite rapidly over the first 2.5 h while **13** converted more slowly to **11**. At this point, the solution was seeded


with **11** (1 wt%), initiating a crystallization event. After 40 h at 23°C , all mono-*N*-Boc and di-*N*-Boc isomers besides **13** and **11** were consumed, and a ratio of 5/84/11 for **13**/**11**/**1** was observed. Filtration gave a solid consisting of >95% **11**.¹⁹ Since product solubility in acetonitrile (ACN) was low, a re-slurry in ACN gave **11** with >98% purity in 75% isolated yield.¹⁹ Here, terminus differentiation of C_2 -symmetric di-Boc isomer **13**, the most significant component of the di-Boc mixture, was made possible through crystallization-induced protection of mono-Boc **11** against further de-Boc to PIB. Without crystallization of **11**, a statistical 1 : 2 : 1 ratio of di/mono/PIB would have been generated (Fig. 2). Therefore, both Horeau amplification (di-Boc stage) and crystallization-induced protection (de-Boc stage) were required to deliver simultaneous regioselective benzimidazole functionalization and desymmetrization. To further increase the yield of the desymmetrization reaction to 94%, the conditions in Scheme 4 were employed, taking advantage of the even lower solubility of Boc-PIB **11** in ACN compared to MTBE. Overall, this di-Boc/mono-de-Boc PIB desymmetrization tactic provided a high isolated yield of a single down-mono-Boc product **11** out of the six species initially observed in attempted mono-Boc protection. While selective protection simplified the problem of PIB prodrug synthesis, regioselective functionalization of the remaining unprotected benzimidazole in **11** remained a formidable challenge (Fig. 3).

Direct alkylation of Boc-PIB **11** with chloromethyl esters was feasible and used successfully for early syntheses of PIB prodrugs (Fig. 2).⁴ However, regioselectivities were poor and yields for the alkylation step variable after significant optimization efforts. Despite very limited precedent for regioselective benzimidazole formaldehyde adduct formation/acylation,²⁰ the reversible nature of such an adduct offered potential benefits that could prove advantageous. To probe this strategy, Boc-PIB **11** was treated with paraformaldehyde and *i*-Pr₂NEt in DMF (Scheme 5), then acylated with acid chloride **16**.

Table 1 Acylation leaving group screen results

Reagent	Leaving group (LG)	Temp ($^\circ\text{C}$)	Time (h)	Conversion (%)	17 : 18 ratio
21	OSu	23	18	20	1.8 : 1
22	4-NO ₂ PhO	23	2	35	1.7 : 1
23	OAt	0	1	35	4.5 : 1
24	C ₆ F ₅ O	-15	4	62	8 : 1
16	Cl	-15	1	95	20 : 1






Scheme 6 Preparation of key intermediate 19.

While good conversion to desired product was observed (85% overall yield), a disappointing 1.8 : 1 ratio of benzimidazole regioisomers **17** and **18** resulted, suggesting poor selectivity in the hydroxymethylation step and/or equilibration during the acylation. Undeterred by this preliminary result, Boc-PIB formaldehyde adduct **19/20** mixture was isolated by precipitation from EtOAc/MTBE/hexanes for investigation of

acylation leaving group identity (Table 1).²¹ Standard acylating conditions (*i*-Pr₂NEt, DMAP) were chosen as a basis for comparison between the acylating reagents, resulting in a wide range of reaction rates and product ratios. Reaction temperature was chosen for each acylating reagent to afford some conversion to product in order to measure the product isomer ratios. An increase in leaving group propensity resulted in greater conversion to the product isomer mixture as well as higher regioselectivity. With a relatively poor leaving group (OSu) in **21**, the reaction reached 20% conversion after 18 h at 23 °C, and a similar product ratio was observed as in the 1-pot reaction (1.8 : 1). Employing the original highly electrophilic acid chloride **16** vastly improved rate (95% conversion after 1 h at -15 °C) and surprisingly improved the isomer ratio to 20 : 1 in favor of the desired product. Since conditions for the acylation were nearly identical to the one-pot reaction, the improved regioselectivity clearly resulted from isolation of the solid formaldehyde adduct. Therefore, the hydroxymethylation constituted a second consecutive crystallization-induced selective reaction.²¹



Scheme 7 Functionalization strategies used to prepare prodrugs of PIB from **19**. Condition A: (i) DMAP (5 mol%), DIEA (3.0 equiv.), acid chloride (2.5 equiv.), THF, -30 °C; (ii) 2 : 1 CH₂Cl₂ : TFA, RT. Condition B: (i) LiHMDS (1.9 equiv.), THF, *T* < -65 °C then acid chloride (2–2.5 equiv.); (ii) 2 : 1 CH₂Cl₂ : TFA, RT. Condition C: (i) **28** (5.0 equiv.), tetrazole (5.0 equiv.), MeCN, -40 °C to 0 °C then H₂O₂ (10 equiv.); (ii) 2 : 1 CH₂Cl₂ : TFA, RT. Hydrogenolyses: Pd/C (0.7 to 5 mol%), H₂ (50 psi), RT, solvent (4–10 mL g⁻¹). See ESI† for detailed procedures.



While the DMF/paraformaldehyde conditions provided adequate material for preliminary studies, a more convenient formaldehyde adduct formation was desired to avoid DMF distillation on larger scale (Scheme 6). Reaction of Boc-PIB **11** with aqueous formaldehyde in EtOAc in the absence of base was found to give a high mass balance of hydroxymethylation product (>10 : 1 **19/11** ratio by ^1H NMR in DMSO),²² providing key intermediate **19** in 99% yield.

Having secured a robust and scalable procedure for the synthesis of compound **19**, we proceeded to investigate its use in the preparation of lead prodrugs of PIB.⁴ The encouraging results observed in the model system (Table 1) provided a useful starting point for the acylation of **19** with more complex structures. In order to enable a variety of potential prodrug classes, several different methods for their introduction were explored from hydroxymethyl intermediate **19**. We initially examined mild acylation conditions using DMAP and Hünig's base in THF at $-30\text{ }^\circ\text{C}$, which provided high regioselectivity for the desired regioisomer (**25** : **26** = >**20** : **1**; Scheme 7, Condition A). To improve the isolation of higher purity products, however, we ultimately employed a stronger base at lower temperatures (LiHMDS, $-65\text{ }^\circ\text{C}$; Scheme 7, Condition B), which offered an improved reaction profile at the expense of incomplete conversion and slightly decreased regioselectivity (**25** : **26** = **10** : **1**). A Boc-deprotection of the crude material preceded efficient chromatographic separation of the regioisomers, affording the penultimate dibenzylphosphate intermediate **25** in 62% yield over 3 steps from **11**. To prepare the trimethyl "lock" prodrug **3**,²³ the cryogenic option (condition B) cleanly afforded the acylation product with high levels of selectivity when using acid chloride **27** (Scheme 7, **29** : **1** isomer ratio) to give an 84% isolated yield of the desired regioisomer over a similar 3-step sequence. A final hydrogenolysis with Pd/C gave the desired free phosphoric acids **2** and **3** in 83% and 64% yields, respectively.²⁴

To prepare phosphoxymethyl prodrug **4** from key intermediate **19**, a third functionalization strategy was required that would rapidly and selectively forge a P–O bond. After several failed attempts to directly form this bond at the phosphate oxidation state, an efficient phosphite formation was realized by employing dibenzylphosphoramidite reagent **28** with tetrazole as base (Condition C, Scheme 7).²⁵ Following addition of hydrogen peroxide and subsequent de-Boc of the resulting crude phosphate, the dibenzylphosphoxymethyl product was obtained in good yield (65%). Benzyl hydrogenolysis proceeded without incident, giving PIB prodrug **4** in 91% yield (Scheme 7).²⁴

Conclusion

The initial synthetic routes to prodrugs **2–4** employed unselective direct alkylations of PIB **1** or Boc-PIB **11** with the requisite chloromethyl esters, where tedious separation of mixtures resulted in low overall yields.⁴ Ultimately, the development of a selective route to key intermediate **19** facilitated regioselective preparation of these lead prodrugs from PIB **1** and suitably positioned them for consideration as clinical candidates. The identification of high-yielding functionalization reactions of **19**

and subsequent phosphate deprotection completed the syntheses of prodrugs **2–4**, improving overall yields from 6–11% to 44–56% from PIB **1**. This desymmetrization strategy could benefit the synthesis of other PIB prodrugs and other di-imidazole and di-benzimidazole analogs for HCV,⁴ as well as fluorescent sensors²⁶ and ligands for organometallic complexes.²⁷ Furthermore, extension of this concept from diheterocycles to other compound classes, for example, C_2 -symmetric diols,¹³ could also be envisioned. Finally, the desymmetrization tactic employed here to differentiate the homotopic termini of PIB **1** highlights the importance of considering classical and perhaps under-utilized strategies such as statistical amplification and exploitation of solubility differences for selectivity in even the most complex chemical settings.

Data availability

Details of experimental conditions, ^1H , ^{13}C , ^{31}P , and ^{19}F NMR spectra for all new compounds, and HPLC/LCMS spectra for select compounds, are available in the ESI.

Author contributions

E. A. V., S. N. G., J. H., R. C. K., J. T. R., and B. H. S. designed and performed the experiments; J. E. W. characterized compounds for structure confirmation; J. J. and D. A. D. supervised the project; E. A. V., S. N. G., and J. H. co-wrote the manuscript.

Conflicts of interest

The manuscript was written through contributions of all authors. All authors have given approval to the final version of the manuscript. All authors are employees of AbbVie. The design, study conduct, and financial support for this research were provided by AbbVie. AbbVie participated in the interpretation of data, review, and approval of the publication.

Acknowledgements

We thank the AbbVie Structural Chemistry group for compound characterization support.

References

- 1 See www.mavyret.com.
- 2 J. Huff and R. Andersen, Glecaprevir/Pibrentasvir: The First 8-Week, Pangenotypic HCV Treatment Regimen for Patients 12 Years of Age and Older, *Ann. Pharmacol.*, 2019, 1–15.
- 3 For a review of properties of drug molecules "beyond the rule of 5," see: D. A. DeGoey, H.-J. Chen, P. B. Cox and M. D. Wendt, Beyond the Rule of 5: Lessons Learned from AbbVie's Drugs and Compound Collection, *J. Med. Chem.*, 2018, **61**, 2636–2651.
- 4 J. T. Randolph, E. A. Voight, S. N. Greszler, B. E. Uno, J. N. Newton, K. M. Gleason, D. Stolarik, C. Van Handel,



- D. A. J. Bow and D. A. DeGoe, Prodrug Strategies to Improve the Solubility of the HCV NS5A Inhibitor Pibrentasvir (ABT-530), *J. Med. Chem.*, 2020, **63**, 11034–11044.
- 5 Complex NMR spectra with significant interpretation challenges characterized PIB and most of its derivatives; see ref. 4, 6, and ESI† for details.
- 6 R. Wagner, J. T. Randolph, S. V. Patel, L. Nelson, M. A. Matulenko, R. Keddy, J. K. Pratt, D. Liu, A. C. Krueger, P. L. Donner, D. K. Hutchinson, C. Flentge, D. Betebenner, T. Rockway, C. J. Maring, T. I. Ng, P. Krishnan, T. Pilot-Matias, C. Collins, N. Panchal, T. Reisch, T. Dekhtyar, R. Mondal, D. F. Stolarik, Y. Gao, W. Gao, D. A. Beno and W. M. Kati, Highlights of the Structure–Activity Relationships of Benzimidazole Linked Pyrrolidines Leading to the Discovery of the Hepatitis C Virus NS5A Inhibitor Pibrentasvir (ABT-530), *J. Med. Chem.*, 2018, **61**, 4052–4066.
- 7 For a recent review of the Horeau principle and applications, see: A. M. Harned, From determination of enantiopurity to the construction of complex molecules: The Horeau principle and its application in synthesis, *Tetrahedron*, 2018, **74**, 3797–3841.
- 8 S. R. Magnuson, Two-Directional Synthesis and its Use in Natural Product Synthesis, *Tetrahedron*, 1995, **51**, 2167–2213.
- 9 C. S. Poss and S. L. Schreiber, Two-Directional Chain Synthesis and Terminus Differentiation, *Acc. Chem. Res.*, 1994, **27**, 9–17.
- 10 T. R. Hoye and Z. Ye, Highly Efficient Synthesis of the Potent Antitumor Annonaceous Acetogenin (+)-Parviflorin, *J. Am. Chem. Soc.*, 1996, **118**, 1801–1802.
- 11 S. D. Burke and L. Jiang, Formal Synthesis of Uvaricin via Palladium-Mediated Double Cyclization, *Org. Lett.*, 2001, **3**, 1953–1955.
- 12 B. C. Austad, A. C. Hart and S. D. Burke, Halichondrin B: synthesis of the C(37)-C(54) subunit, *Tetrahedron*, 2002, **58**, 2011–2026.
- 13 S. B. Han, A. Hassan, I. S. Kim and M. J. Krische, Total Synthesis of (+)-Roxaticin via C-C Bond Forming Transfer Hydrogenation: A Departure from Stoichiometric Chiral Reagents, Auxiliaries, and Premetalated Nucleophiles in Polyketide Construction, *J. Am. Chem. Soc.*, 2010, **132**, 15559–15561.
- 14 For a recent review, see: A. J. Metrano and S. J. Miller, Peptide-Based Catalysts Reach the Outer Sphere through Remote Desymmetrization and Atroposelectivity, *Acc. Chem. Res.*, 2019, **52**, 199–215.
- 15 Decreasing the temperature from 23 °C to –35 °C in THF enhanced the down/up selectivity from 3 : 1 (Scheme 1) to 5 : 1 (Scheme 2) while maintaining a reasonable rate. Further decreasing the temperature led to solubility issues, while other solvents (MeTHF, MTBE, ACN, DCM, toluene) led to poor selectivity and/or solubility issues.
- 16 J. P. Vigneron, M. Dhaenens and A. Horeau, Maximizing optical purity of a partially resolved product without using a chiral compound, *Tetrahedron*, 1973, **29**, 1055–1059.
- 17 The only additional known example of the Horeau principle being invoked to rationalize selectivity outside the context of enantioselective synthesis is in Hoye's report on alkene geometry statistical amplification: T. R. Hoye and J. C. Sudhadolnik, Stereocontrolled synthesis of 2,5-linked bistetrahydrofurans via the triepoxide cascade reaction, *Tetrahedron*, 1986, **42**, 2855–2862.
- 18 For a recent example of crystallization protecting against undesired double reaction, see: T. Seo, K. Kubota and H. Ito, Selective Mechanochemical Monoarylation of Unbiased Dibromoarenes by in Situ Crystallization, *J. Am. Chem. Soc.*, 2020, **142**, 9884–9889.
- 19 The initially isolated solid contained a 3.4/95.3/1.3 ratio of **13/11/1**, while the mother liquor was 36.7/46.7/16.6 (9% 11 loss by HPLC). Then, the reslurry in ACN (5 mL/g, slow cooling from 75 °C to 23 °C with 1 h age prior to filtration), showed a 43.1/38.9/18 ratio of **13/11/1** in the supernatant before filtration. See the ESI† for details.
- 20 For example, see: J. C. Sih, W. B. Im, A. Robert, D. R. Graber and D. P. Blakeman, Studies on (H⁺-K⁺)-ATPase Inhibitors of Gastric Acid Secretion. Prodrugs of 2-[(2-Pyridinylmethyl) sulfinyl]-benzimidazole Proton-Pump Inhibitors, *J. Med. Chem.*, 1991, **34**, 1049–1062.
- 21 This selective benzimidazole hydroxymethylation can be considered an unusual example of a Crystallization-Induced Diastereomer Transformation (CIDT): K. M. J. Brands and A. J. Davies, Crystallization-Induced Diastereomer Transformations, *Chem. Rev.*, 2006, **106**, 2711–2733.
- 22 Interpretation of **19/20** identity was complicated in that varying degrees of hydrolysis back to **11** and solution-state interconversion were consistently observed in attempts to monitor reactions or characterize the material. Therefore, although a solid isolation of **19** was performed, its identity was assigned based on isolated acylation/de-Boc product characterization results. See the ESI† for details. These persistent byproducts appeared to be derived from the acid chloride without incorporation of PIB, which led us to propose ketene-derived products or anhydrides that were difficult to remove without reverse-phase chromatography.
- 23 Acid chloride **27** was prepared via an abbreviated 4-step route that avoided the oxidation/reduction steps in the published route: M. G. Nicolaou, C. Yuan and R. T. Borchardt, Phosphate Prodrugs for Amines Utilizing a Fast Intramolecular Hydroxy Amide Lactonization, *J. Org. Chem.*, 1996, **61**, 8636–8641. See the ESI† for details.
- 24 See the ESI† for detailed reaction and purification procedures.
- 25 W. Bannwarth and A. Trzeciak, A Simple and Effective Chemical Phosphorylation Procedure for Biomolecules, *Helv. Chim. Acta*, 1987, **70**, 175–186.
- 26 Y.-C. Wu, J.-Y. You, J.-C. Xie, S.-L. Li, D. Cao and Z.-Y. Wang, Colorimetric and ratiometric fluorescent sensor for F⁻ based on benzimidazole-naphthalene conjugate: Reversible and reusable study & design of logic gate function, *Dyes Pigm.*, 2017, **140**, 47–55.
- 27 C. Rajnak, J. Titis, O. Fuhr, M. Ruben and R. Boca, Low spin Fe(II) complexes formed of monosubstituted 2,6-bis(2-benzimidazolyl)pyridine ligands, *Polyhedron*, 2017, **123**, 122–131.

